McMaster University Medical Center
Hamilton, Ontario, L8S 4K1, Canada
Location status: Recruiting
NCT Number: NCT01650311
Alterations in normal serotonin (5-hydroxytryptamine;5-HT) signaling have been reported in ulcerative colitis (UC) and Crohn's disease (CD). Studies report an increase in enterochromaffin (EC) cell, main source of 5-HT in the gut, numbers in CD and UC patients. Up-regulated expression of mucosal Tryptophan hydroxylase (TPH)-1, catalytic enzyme in 5-HT production, messenger RNA (mRNA) have been found in CD patients in remission who are suffering the irritable bowel syndrome (IBS)-like symptoms. Alterations in normal 5-HT signaling has also been reported in animal models of inflammatory bowel disease (IBD). Thus, the aim of the proposed research project will be to study the alterations in 5-HT signalling accompanying GI inflammatory conditions, such as IBD.
Interested in participating?
Request Info19 year–85 year
All sexes
Observational
Hamilton, Ontario, L8S 4K1, Canada
Location status: Recruiting
The gut produces approximately 95% of serotonin (5-hydroxytryptamine; 5-HT) found in the human body; where, it is a very important mucosal signaling molecule participating in gut motility, sensation, and secretion.The vast majority of the gut-derived 5-HT is produced by specialized epithelial cells of The GI tract, called enterochromaffin (EC) cells. EC cells produce 5-HT from dietary tryptophan, this process involves the rate limiting enzyme tryptophan hydroxylase (TPH) 1, once produced this 5-HT can be released into the gut lumen, surrounding tissue and can enter the blood circulation.5-HT mediates many gastrointestinal functions, including secretion and peristalsis, by acting on a diverse range of 5-HT receptors. Five of the seven known receptor families of 5-HT (5-HT1, 5-HT2, 5-HT3, 5-HT4 and 5-HT7) are expressed in the gut.
5-HT has been evaluated in IBD and in animal models of colitis. An increase in numbers of EC cells expressing 5-HT is observed in CD and UC patients and consumption of selective 5-HT reuptake inhibitors is associated with microscopic colitis. In the present study, we plan to investigate the key elements of mucosal 5-HT signaling in CD patients for a better understanding of the role of 5-HT in pathogenesis of IBD.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At the time of sample collection
Levels of the gene expression and/or protein quantifications of the enzyme Tph1 will be measured to assess production of 5HT.
Time frame: At the time of sample collection
Levels of the various serotonin receptors will be measured to assess changes in serotonin signaling
Contact information is provided by the study sponsor or research team.
Jensine Grondin, MSc.
CONTACT
905-525-9140 ext. 22970
Tyler Seto, BSc
CONTACT
905-525-9140 ext. 22970
McMaster University
Other
Acronym: IBD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001184
Chrohn's Disease, Colitis
Bethesda, Maryland, United States
View Trial DetailsNCT07242248
Colitis, Colitis, Ulcerative
Harrow, United Kingdom
View Trial DetailsNCT07102368
Colitis, Colitis, Ulcerative
Berlin, Germany
View Trial DetailsNCT03816345
Arthritis, Arthritis, Psoriatic
Birmingham, Alabama, United States
View Trial Details